Medeze Group

Medeze Group EBITDA per Share

The EBITDA per Share of Medeze Group (MEDEZE.BK) as of Oct 27, 2026 is 0.21 THB. In the previous year, EBITDA per Share was 0.35 THB — a change of -39.15% (lower).

EBITDA per Share

0.21THB

YoY

-39.15%

Last updated:

EBITDA per Share of Medeze Group is 2025 0.21 THB. EBITDA per Share of Medeze Group was 2024 0.35 THB. It decreases by -39.15% lower compared to the previous year.

The Medeze Group EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
0.38 THB
Jan 1, 2019
0.36 THB
Jan 1, 2020
0.38 THB
Jan 1, 2021
0.12 THB
Jan 1, 2022
0.25 THB
Jan 1, 2023
0.28 THB
Jan 1, 2024
0.35 THB
Jan 1, 2025
0.21 THB
The Medeze Group EBITDA per Share history
YEAREBITDA per ShareYoY
0.21THB-39.15%
0.35THB+23.28%
0.28THB+14.68%
0.25THB+102.09%
0.12THB-67.38%
0.38THB+4.13%
0.36THB-4.35%
0.38THB-1.17%
0.38THB—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medeze Group Stock analysis

What does Medeze Group do? Medeze Group PLC operates as a mesenchymal stem cell bank in Thailand, offering stem cell storage services from umbilical cord tissue and adipose tissue, alongside umbilical cord blood storage. The company provides stem cell analysis, separation, cultivation, and storage services, including immune cell potential testing for Natural killer cells. Its white blood cell potential testing service segment evaluates NK cell performance and count, while the other services segment delivers research, data collection on human cellular activities, and medical laboratory tests. The sales of products segment generates revenue through dietary supplements, cosmetics, and dermo cosmetics. The company's primary customers are individuals seeking stem cell storage for future medical use, as well as those requiring immune cell testing and research services. The stem cell sample collection service segment targets expectant parents and medical institutions for cord blood and tissue storage. The white blood cell potential testing service segment serves healthcare providers and patients interested in NK cell analysis. The sales of products segment appeals to consumers purchasing dietary supplements and cosmetic products. Medeze Group PLC's revenue streams are derived from multiple segments: stem cell storage services, immune cell testing, research and laboratory services, and product sales. The stem cell sample collection and storage services form the core offering, while the white blood cell potential testing and other services provide additional value. Product sales contribute to revenue through the distribution of dietary supplements, cosmetics, and dermo cosmetics, targeting both individual consumers and healthcare-focused markets. Medeze Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medeze Group stock

EBITDA per Share of Medeze Group is 0.21 THB in 2025.

EBITDA per Share of Medeze Group changed from 0.35 THB to 0.21 THB, representing a -39.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Medeze Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Medeze Group

All Key Metrics — Medeze Group